Abstract LB-302: A comprehensive study of translational research and safety exploration of the vascular disrupting agent (VDA) AVE8062 in combination with cisplatin administered every 3 weeks to patients with advanced solid tumors
Jean‐Charles Soria(Inserm), Luca Gianni(Fondazione Michelangelo), Nathalie Lassau(Centre National de la Recherche Scientifique), E. Borghi(Sanofi (France)), Antonella Perotti(European Institute of Oncology), Christophe Massard(Institut Gustave Roussy), C. Sessa(Vita-Salute San Raffaele University), Jean‐Pierre Armand(Institut Gustave Roussy), Françoise Farace(Institut Gustave Roussy)
Cited by 8
Related Papers
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Rociletinib in <i>EGFR</i>-Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2015|664